Rhabdomyosarcoma, or RMS, is a cancer that develops in cells destined to become skeletal muscle and is among the most common soft-tissue cancers affecting children under 15. Around 55 children are diagnosed with the disease in the United Kingdom each year. Unlike many cancers in adults, which are frequently associated with the accumulation of mutations over decades or with environmental exposures, childhood cancers often arise from genetic and developmental errors occurring as tissues form. RMS is commonly divided into fusion-positive and fusion-negative disease, based on whether tumour cells contain a rearrangement joining two genes that are normally separate. The best-known alteration involves PAX3 or PAX7 fused with FOXO1, producing an abnormal transcription factor that can disrupt normal cell development and promote tumour formation.

The presence of a PAX-FOXO1 fusion is strongly associated with an unfavourable outcome. Children whose tumours carry the fusion generally have lower survival rates than those whose tumours do not, even when treated with intensive chemotherapy, surgery and radiotherapy. This distinction has become an important part of risk assessment and treatment planning. Yet the classification is not absolute. Some children with fusion-negative RMS develop rapidly progressive, treatment-resistant disease, while others with apparently similar tumours respond more successfully. Until now, the biological explanation for this difference has remained incomplete, raising concerns that conventional testing may be concealing a high-risk population within the group considered to have lower-risk disease.

In the study, published in Cancer Research on 19 August 2026, scientists from the Wellcome Sanger Institute, the University of Cambridge, Great Ormond Street Hospital and University College London analysed RMS tumours using genomic methods capable of resolving differences between individual cancer cells. The research cohort included four children with fusion-negative lethal disease, four with fusion-positive disease and eight children with fusion-negative tumours who remained alive. This design enabled the team to compare the molecular characteristics of aggressive and less aggressive tumours across the two major genetic categories, while examining whether the behaviour of individual cells matched the broader diagnosis assigned to each tumour.

A central technique was single-cell RNA sequencing, which measures the RNA molecules present in individual cells. RNA provides a snapshot of which genes are active, meaning that researchers can use it to determine whether a cell is behaving like a developing muscle cell, a proliferating cancer cell or another specialised population within the tumour. Bulk sequencing, in which genetic material from thousands or millions of cells is mixed together, can obscure rare but important groups. A small population of highly aggressive cells may produce only a faint signal in an averaged molecular profile. By analysing cells separately, the researchers were able to identify these hidden populations and examine the gene networks associated with their growth, developmental state and resistance to normal controls.

The results revealed that aggressive fusion-negative tumours contained cells with gene-expression programmes closely resembling those found in fusion-positive high-risk RMS. In other words, the cells appeared to have reached a similar biological destination through different genetic routes. The absence of the PAX-FOXO1 fusion did not guarantee that the tumour lacked the cellular features linked to aggressive behaviour. Instead, some fusion-negative cancers showed a convergent cell state, marked by coordinated activity across multiple pathways that influence cell identity, proliferation and the ability to maintain an immature, tumour-promoting phenotype. This convergence may explain why tumours carrying different initiating alterations can ultimately behave in similar ways in children.

The investigators also identified rare genetic changes in aggressive fusion-negative tumours that affect cellular pathways overlapping with those disrupted in fusion-positive disease. These alterations may not create the same fusion protein, but they can disturb related biological systems and push developing muscle cells towards a comparable malignant state. The finding supports a model in which RMS is not driven by one universal mutation. Instead, several independent genetic events may interfere with developmental programmes that normally guide muscle formation, producing a shared state of cellular immaturity and uncontrolled growth. Such a state could be more informative for predicting clinical behaviour than the presence or absence of a single risk marker alone.

To understand how these aggressive cells were arranged inside tumours, the researchers used spatial transcriptomics. This approach preserves information about the location of cells within tissue while measuring gene activity, allowing scientists to connect molecular identity with physical organisation. Rather than viewing a tumour as a uniform mass, spatial analysis treats it as an ecosystem made up of distinct cell populations occupying different niches. The study showed how aggressive populations were organised within the cancer tissue, offering clues about how neighbouring cells and the tumour environment may support disease progression. Mapping these patterns could eventually help researchers determine whether particular regions of a tumour are especially likely to survive treatment or seed a relapse.

The discovery may have consequences for diagnosis and therapy, although it will require validation in much larger groups of patients before it can change clinical practice. Researchers are expanding the work to hundreds of additional RMS samples in an effort to find more of the rare genetic pathways that can generate the convergent aggressive state. If reliable molecular markers can be developed, tumour testing could be extended beyond fusion status to include the activity of high-risk cell programmes. Children whose disease currently appears non-high-risk might then be identified for closer monitoring or treatment adjustments, while those unlikely to benefit from additional chemotherapy could potentially avoid some of its long-term toxicity. Any change in treatment would need to be guided by clinical trials, because increasing therapy intensity can itself cause serious harm.

The researchers also hope that the shared markers found on aggressive RMS cells could provide targets for precision treatments, including immunotherapies such as CAR-T cell therapy. CAR-T treatment involves collecting a patient’s T cells and genetically engineering them to recognise a molecule on cancer cells before returning them to the body. For this strategy to work safely, the target must be present on tumour cells but absent, or present at much lower levels, in essential healthy tissues. The newly identified cell-state markers could help guide the search for such targets, although the study does not demonstrate that a CAR-T therapy for RMS is ready for patients. The immediate significance of the research is the biological insight: aggressive childhood cancers that look different genetically may share a vulnerable molecular identity, creating a possible foundation for earlier detection and more personalised treatment.

Subject of Research:
Aggressive and high-risk childhood rhabdomyosarcoma, including fusion-negative tumours with high-risk cellular features.

Article Title:
High-Risk Rhabdomyosarcomas Feature a Convergent Cell State

News Publication Date:
19 August 2026

Web References:
Wellcome Sanger Institute: https://www.sanger.ac.uk/
Wellcome: https://wellcome.org/
Cancer Research UK: https://www.cancerresearchuk.org/
Alice’s Arc: https://www.alicesarc.co.uk/

References:
Whitfield, H. J. et al. (2026), “High-Risk Rhabdomyosarcomas Feature a Convergent Cell State,” Cancer Research. DOI: 10.1158/0008-5472.CAN-25-4403.
Skapek, S. X. et al. (2013), “PAX-FOXO1 fusion status drives unfavourable outcome for children with rhabdomyosarcoma: a Children’s Oncology Group report,” Pediatric Blood & Cancer. DOI: 10.1002/pbc.24532.
Children with Cancer UK, “Rhabdomyosarcoma Overview.”

Keywords:
Rhabdomyosarcoma, childhood cancer, cancer genetics, PAX-FOXO1, fusion-negative RMS, single-cell RNA sequencing, spatial transcriptomics, cancer biology, precision medicine, immunotherapy, CAR-T cell therapy, oncology

In the landscape of pediatric cancers, Ewing sarcoma presents a dire challenge for researchers and clinicians. This particular bone cancer, which typically strikes children and adolescents, is devastating in its consequences and has often baffled those who confront it on a medical level. The new dataset from the Kids First initiative, developed under the meticulous leadership of Dr. Joshua D. Schiffman, integrates whole genome sequencing data on approximately 375 Ewing sarcoma trios. This exhaustive analysis endeavors to pinpoint genes that may predispose individuals to this malignancy. The ramifications of these findings could be monumental, affording researchers new insights into the genetic underpinnings of Ewing sarcoma, which could ultimately lead to novel therapeutic avenues for treatment and prevention.

As research in Ewing sarcoma continues to unfold, another critical area of concern is congenital disorders, highlighted by the newly released dataset focused on Cornelia de Lange Syndrome (CdLS). This rare but impactful developmental disorder is characterized by a variety of developmental delays, cognitive impairments, and distinct structural birth defects. Headed by Dr. Ian Krantz, the corresponding dataset encapsulates rich genetic and phenotypic data collected from around 400 individuals and their families diagnosed with CdLS. By cataloging the genetic variables associated with this syndrome, the dataset aims to unravel the complexities of human embryonic development, thereby illuminating the genetic roots of not only CdLS but also other similar diagnoses that may exhibit overlapping features.

The launch of these datasets signifies a leap forward in collaborative pediatric research. The Kids First Data Resource Center stands as a beacon of hope, harnessing over 188,000 data records that are now accessible to scientists and researchers engaged in relevant fields around the world. This centralized repository assembles harmonized genomic sequencing data, facilitating an expansive research network aimed at addressing pediatric cancers and congenital disorders from a comprehensive viewpoint. By connecting various research initiatives under one umbrella, Kids First allows for collective data analysis, maximizing the potential for meaningful discoveries that could lead to innovative treatments and preventive strategies.

The potential for these datasets to catalyze breakthroughs in both understanding and treatment cannot be overstated. The power of genomic data in elucidating the pathways that give rise to cancers and genetic disorders lies in its ability to reveal hidden patterns and connections that were previously obscured. For researchers delving into Ewing sarcoma, the identification of specific predisposition genes and genomic markers tied to risk factors like familial cancer history is paramount. This data not only provides groundwork for further lab investigations but also holds promise for clinical applications that could guide screening and surveillance strategies in at-risk populations.

Moreover, as Dr. Krantz and his colleagues sift through genetic data related to Cornelia de Lange Syndrome, the implications extend well beyond the disorder itself. The insights gleaned from understanding the genetic landscape of CdLS may illuminate the genetic architecture of a wide array of congenital disorders that share similar developmental pathways. Consolidated knowledge of these genetic factors can lead to broader implications in terms of diagnosis, management, and possibly even preventive strategies for a myriad of conditions, emphasizing the need for continued research in this domain.

As these datasets become widely utilized, the eyebrows of both researchers and clinicians are likely to raise at the prospect of enriched bioinformatics platforms. Such platforms can analyze large-scale genomic data, allowing for more sophisticated observations that can drive the scientific community towards standardized genomic medicine. By cultivating rich, interoperable datasets, Kids First positions itself at the forefront of medical research aimed at combating some of the most challenging health problems faced by children today.

Further enhancing the accessibility and usability of these datasets is the Kids First DRC Portal. This user-friendly interface invites scientists and researchers globally to explore and utilize the compiled genomic data for their own investigations. The democratization of data not only empowers individual research endeavors but aims to foster collaborative opportunities across institutions, potentially accelerating the pace at which effective therapies can be developed for childhood cancer and congenital disorders.

In conclusion, the release of the new Kids First datasets marks a transformative moment in pediatric research. Aimed at casting light on Ewing sarcoma and Cornelia de Lange Syndrome, these resources serve as a vital link connecting various strands of research intent on mitigating the devastating impact of these conditions. By providing unprecedented access to essential genetic data, the Kids First initiative hopes to usher in a new era of collaboration and innovation within the scientific community, ultimately striving towards improved health outcomes for children afflicted by cancers and genetic disorders.

As researchers continue to dissect this data, the implications of their findings could be profound, serving a twofold purpose: enhancing our understanding of the fundamental aspects of childhood cancers and congenital disorders, while concurrently fostering an environment conducive to groundbreaking therapeutic developments that will change the lives of countless children and their families worldwide.

Subject of Research: Pediatric cancers and congenital disorders
Article Title: New Datasets from Kids First: Unraveling Childhood Cancers and Congenital Disorders
News Publication Date: October 2023
Web References: Kids First Data Resource Center
References:
Image Credits:

Keywords: childhood cancer, congenital disorders, Ewing sarcoma, Cornelia de Lange Syndrome, genetic research, pediatric research, genomic data.